{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:19:28Z","timestamp":1791821968087,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The EVEREST II study reported superior polyp closure rates and visual outcomes using combination standard photodynamic therapy (PDT) with intravitreal ranibizumab in the treatment of polypoidal choroidal vasculopathy (PCV). The optimal PDT protocol remains controversial and it is postulated that less intensive PDT strategies may reduce complications. We aimed to compare the efficacy of reduced and standard-fluence PDT.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Case-control review of 38 consecutive PDT-na\u00efve macular PCV patients who underwent verteporfin PDT using one of two PDT regimens at a tertiary referral centre in an Asian population. Comparison of outcomes between standard-fluence PDT (light dose, 50\u2009J\/cm2; dose rate, 600\u2009mW\/cm2; wavelength, 689\u2009nm PDT applied to the treatment eye for 83\u2009s) and reduced-fluence PDT (light dose, 25\u2009J\/cm2; dose rate, 600\u2009mW\/cm2; wavelength, 689\u2009nm PDT applied to the treatment eye for 42\u2009s). Primary outcome measure was best corrected LogMAR visual acuity (VA). Secondary outcome measures included OCT measurements such as central retinal thickness (CRT), height of subfoveal sub-retinal fluid (SRF), central choroid thickness (CCT), mean number of PDT treatments needed, mean number of anti-VEGF injections needed, polyp closure and recurrence rates.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Of these 38 eyes of 38 patients, an equal number of eyes (19 in each arm) were treated with standard-fluence and reduced-fluence PDT. Mean letter gain at 12\u2009months for the standard-fluence group was 6.0 compared to 4.3 letters for the reduced-fluence group (<jats:italic>p<\/jats:italic>\u2009=\u20090.61). Similar results were observed at all time points. There was no statistically significant difference between the retinal and choroidal anatomical OCT outcomes, rates of polyp closure and recurrences between the two PDT regimens.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Reduced-fluence PDT was comparable to standard-fluence PDT in the treatment of PCV in terms of visual gains, clinical and anatomical OCT outcomes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12886-020-01419-8","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T14:02:41Z","timestamp":1586959361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy"],"prefix":"10.1186","volume":"20","author":[{"given":"Wei Kiong","family":"Ngo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Kitt","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tock Han","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"1419_CR1","first-page":"1","volume":"1","author":"LA Yannuzzi","year":"1900","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1900;1:1\u20138.","journal-title":"Retina."},{"issue":"1","key":"1419_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144(1):15\u201322.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"1419_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453\u201364.","journal-title":"Retina."},{"issue":"11","key":"1419_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Efficacy and safety of Ranibizumab with or without Verteporfin photodynamic therapy for Polypoidal Choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206\u201313.","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"1419_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bjophthalmol-2014-305674","volume":"99","author":"CS Tan","year":"2015","unstructured":"Tan CS, Ngo WK, Chen JP, Tan NW, Lim TH. EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99(5):624\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1419_CR6","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","volume":"111","author":"WM Chan","year":"2004","unstructured":"Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111(8):1576\u201384.","journal-title":"Ophthalmology."},{"issue":"1","key":"1419_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ophtha.2007.02.031","volume":"115","author":"F Gomi","year":"2008","unstructured":"Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115(1):141\u20136.","journal-title":"Ophthalmology."},{"issue":"3","key":"1419_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/01.iae.0000233647.78726.46","volume":"27","author":"Y Hirami","year":"2007","unstructured":"Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 2007;27(3):335\u201341.","journal-title":"Retina."},{"issue":"8","key":"1419_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.4103\/ijo.IJO_174_17","volume":"65","author":"P Rishi","year":"2017","unstructured":"Rishi P, Rishi E, Sharma M, Maitray A, Bhende M, Gopal L, et al. Incidence, outcomes, and risk factors for hemorrhagic complications in eyes with polypoidal choroidal vasculopathy following photodynamic therapy in Indian subjects. Indian J Ophthalmol. 2017;65(8):712\u20138.","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"1419_CR10","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1167\/iovs.02-0604","volume":"44","author":"S Michels","year":"2003","unstructured":"Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44(5):2147\u201354.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1419_CR11","first-page":"835","volume":"120","author":"U Schmidt-Erfurth","year":"2002","unstructured":"Schmidt-Erfurth U, Laqua H, Schl\u00f6tzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120(6):835\u201344.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1419_CR12","first-page":"830","volume":"43","author":"U Schmidt-Erfurth","year":"2002","unstructured":"Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43(3):830\u201341.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"1419_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jcma.2013.10.012","volume":"77","author":"NW Fan","year":"2014","unstructured":"Fan NW, Lau LI, Chen SJ, Yang CS, Lee FL. Comparison of the effect of reduced-fluence photodynamic therapy with intravitreal bevacizumab and standard-fluence alone for polypoidal choroidal vasculopathy. J Chin Med Assoc. 2014;77(2):101\u20137.","journal-title":"J Chin Med Assoc"},{"issue":"5","key":"1419_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.ajo.2011.09.031","volume":"153","author":"M Sagong","year":"2012","unstructured":"Sagong M, Lim S, Chang W. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2012;153(5):873\u201382.","journal-title":"Am J Ophthalmol"},{"key":"1419_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/OPTH.S54578","volume":"8","author":"M Sakurai","year":"2014","unstructured":"Sakurai M, Baba T, Kitahashi M, Yokouchi H, Kubota-Taniai M, Bikbova G, et al. One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Clin Ophthalmol. 2014;8:235\u201341.","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"1419_CR16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.4103\/0301-4738.198856","volume":"64","author":"P Sen","year":"2016","unstructured":"Sen P, Bhende M, Sachidanandam R, Bansal N, Sharma T. Reduced-fluence photodynamic therapy and anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy in an Indian population. Indian J Ophthalmol. 2016;64(12):908\u201313.","journal-title":"Indian J Ophthalmol"},{"key":"1419_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12886-015-0061-8","volume":"15","author":"IY Wong","year":"2015","unstructured":"Wong IY, Shi X, Gangwani R, Zhao P, Iu LP, Li Q, et al. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy. BMC Ophthalmol. 2015;15:66.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"1419_CR18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ajo.2009.09.020","volume":"149","author":"A Yamashita","year":"2010","unstructured":"Yamashita A, Shiraga F, Shiragami C, Ono A, Tenkumo K. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2010;149(3):465\u201371.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1419_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ajo.2012.06.027","volume":"155","author":"A Yamashita","year":"2013","unstructured":"Yamashita A, Shiraga F, Shiragami C, Shirakata Y, Fujiwara A. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;155(1):96\u2013102.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1419_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10384-013-0234-z","volume":"57","author":"Y Yoshida","year":"2013","unstructured":"Yoshida Y, Kohno T, Yamamoto M, Yoneda T, Iwami H, Shiraki K. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2013;57(3):283\u201393.","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"1419_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3928\/23258160-20150909-02","volume":"46","author":"CS Tan","year":"2015","unstructured":"Tan CS, Lim TH, Hariprasad SM. Current Management of Polypoidal Choroidal Vasculopathy. Ophthalmic Surg Lasers Imaging Retina. 2015;46(8):786\u201391.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"11","key":"1419_CR22","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1136\/bjophthalmol-2014-305059","volume":"98","author":"CS Tan","year":"2014","unstructured":"Tan CS, Ngo WK, Lim LW, Lim TH. A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes. Br J Ophthalmol. 2014;98(11):1528\u201333.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"1419_CR23","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00417-016-3333-y","volume":"254","author":"CS Tan","year":"2016","unstructured":"Tan CS, Ngo WK, Lim LW, Tan NW, Lim TH. EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study. Graefes Arch Clin Exp Ophthalmol. 2016;254(10):1923\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"1419_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0039-6257(00)00158-2","volume":"45","author":"U Schmidt-Erfurth","year":"2000","unstructured":"Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45(3):195\u2013214.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"1419_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/sj.eye.6702455","volume":"21","author":"CS Tan","year":"2007","unstructured":"Tan CS, Wong HT, Lim BA, Hee OK, Lim TH. Polypoidal choroidal vasculopathy causing massive suprachoroidal haemorrhage. Eye (Lond). 2007;21(1):132\u20133.","journal-title":"Eye (Lond)"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01419-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-020-01419-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01419-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T23:59:13Z","timestamp":1618444753000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01419-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1419"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01419-8","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"5 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the National Healthcare Group Domain Specific Review Board (DSRB) and conformed to the Tenets of the Declaration of Helsinki. Written, informed consent was obtained from patients prior to initiation of treatment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Wei Kiong Ngo received research support from the National Healthcare Group Clinician Scientist Preparatory Programme (CSPP-16008). He received honoraria from Bayer and Novartis. He also received travel support from Allergan.Dr. Wai Kitt Chee has no financial interests to declare.A\/Prof Colin S. Tan receives travel support from Bayer, Heidelberg Engineering and Novartis. He also receives research support from the NMRC TA NMRC\/TA\/0039\/2015.A\/Prof Tock Han Lim receives travel support from Novartis, Bayer and Heidelberg Engineering.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}